Thanks for the link. I took a look at a white paper on aficamten. It reduces myosin which is ATP dependent thus reducing stiffening and thickening of the heart muscle. ATP overexpression is linked to CCL5. Leronlimab reduces overexpressed ATP via CCL5 downregulation. Myosin is also dependent on CA2+ which leronlimab downregulates. When CA2+ homeostasis is unbalanced as with excessive intracellular CA2+ it can lead to heart attacks and heart arrhythmias due to problems with heart contraction. Of course leronlimab also would curb heart fibrosis and arterial plaques.

Once again leronlimab is king of the hill. It's unfortunate that only this small circle here and a few people at Cytodyn know what leronlimab can do.